These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 766340)

  • 1. A controlled trial of daily and intermittent rifampicin plus ethambutol in the retreatment of patients with pulmonary tuberculosis: results up to 30 months.
    Tubercle; 1975 Sep; 56(3):179-89. PubMed ID: 766340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigations of allergic status and blood counts in Chinese patients receiving daily or intermittent rifampicin in Hong Kong.
    Clin Allergy; 1975 Jun; 5(2):189-99. PubMed ID: 1095248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of daily followed by twice or once weekly regimens of ethambutol and rifampicin in retreatment of patients with pulmonary tuberculosis. The results at 1 year. A cooperative tuberculosis chemotherapy study in Poland.
    Tubercle; 1975 Mar; 56(1):1-26. PubMed ID: 1096388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled trial of 6- and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong.
    Tubercle; 1975 Jun; 56(2):81-96. PubMed ID: 1103400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong.
    Aquinas M; Allan WG; Horsfall PA; Jenkins PK; Hung-Yan W; Girling D; Tall R; Fox W
    Br Med J; 1972 Mar; 1(5803):765-71. PubMed ID: 4259217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Split-drug regimens for the treatment of patients with sputum smear-positive pulmonary tuberculosis--a unique approach.
    Santha T; Rehman F; Mitchison DA; Sarma GR; Reetha AM; Prabhaker R;
    Trop Med Int Health; 2004 May; 9(5):551-8. PubMed ID: 15117298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis. First report.
    Am Rev Respir Dis; 1978 Aug; 118(2):219-28. PubMed ID: 100029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled trial of 6-month and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. The results up to 30 months.
    Am Rev Respir Dis; 1977 May; 115(5):727-35. PubMed ID: 857713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hong Kong Treatment Services-Royal Postgraduate Medical School-British Medical Research Council Co-operative study of rifampicin plus ethambutol in daily and intermittent regimens. Clinical observations on adverse reactions.
    Girling DJ
    Scand J Respir Dis Suppl; 1973; 84():119-24. PubMed ID: 4522064
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of a daily and three intermittent retreatment regimens for pulmonary tuberculosis administered under programme conditions.
    Hong YP; Kim SC; Chang SC; Kim SJ; Jin BW; Park CD
    Tubercle; 1988 Dec; 69(4):241-53. PubMed ID: 3076999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of daily followed by twice- or once-weekly regimens of ethambutol and rifampicin in the retreatment of patients with pulmonary tuberculosis: second report.
    Tubercle; 1976 Jun; 57(2):105-13. PubMed ID: 822547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlled trial of intermittent regimens of rifampicin plus isoniazid for pulmonary tuberculosis in Singapore.
    Lancet; 1975 Dec; 2(7945):1105-9. PubMed ID: 53598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
    Wada M
    Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A controlled clinical trial of daily and intermittent regimens of rifampicin plus ethambutol in the retreatment of patients with pulmonary tuberculosis in Hong Kong. A Hong Kong Tuberculosis Treatment Services/Brompton Hospital/British Medical Research Council investigation.
    Tubercle; 1974 Mar; 55(1):1-27. PubMed ID: 4283482
    [No Abstract]   [Full Text] [Related]  

  • 15. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council.
    Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):700-6. PubMed ID: 1901199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.
    Fregonese F; Ahuja SD; Akkerman OW; Arakaki-Sanchez D; Ayakaka I; Baghaei P; Bang D; Bastos M; Benedetti A; Bonnet M; Cattamanchi A; Cegielski P; Chien JY; Cox H; Dedicoat M; Erkens C; Escalante P; Falzon D; Garcia-Prats AJ; Gegia M; Gillespie SH; Glynn JR; Goldberg S; Griffith D; Jacobson KR; Johnston JC; Jones-López EC; Khan A; Koh WJ; Kritski A; Lan ZY; Lee JH; Li PZ; Maciel EL; Galliez RM; Merle CSC; Munang M; Narendran G; Nguyen VN; Nunn A; Ohkado A; Park JS; Phillips PPJ; Ponnuraja C; Reves R; Romanowski K; Seung K; Schaaf HS; Skrahina A; Soolingen DV; Tabarsi P; Trajman A; Trieu L; Banurekha VV; Viiklepp P; Wang JY; Yoshiyama T; Menzies D
    Lancet Respir Med; 2018 Apr; 6(4):265-275. PubMed ID: 29595509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A controlled clinical trial of small daily doses of rifampicin in the prevention of adverse reactions to the drug in a once-weekly regimen of chemotherapy in Hong Kong: second report:-the results at 12 months.
    Tubercle; 1974 Sep; 55(3):193-210. PubMed ID: 4620298
    [No Abstract]   [Full Text] [Related]  

  • 19. Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Second report: the results up to 24 months. Hong Kong Chest Service/British Medical Research Council.
    Tubercle; 1982 Jun; 63(2):89-98. PubMed ID: 6758252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A comparative study on clinical efficacy of rifampicin (RFP), ethambutol (EB) and ethionamide (1321 TH) in retreatment of pulmonary tuberculosis. Report of the 13th series study part B].
    Kekkaku; 1972 May; 47(5):139-44. PubMed ID: 5042532
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.